P61964 (WDR5_HUMAN) Homo sapiens (Human)

WD repeat-containing protein 5 UniProtKBProtein AtlasInterProSTRINGInteractive Modelling

334 aa; Sequence (Fasta) ; 71 identical sequences

Available Structures

166 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
X-ray structure of WDR5 bound to the WDR5 win motif peptide Heteromer
10-334
100SO4;
Crystal structure of human WDR5 in complex with WDR5 Heteromer
10-334
100
Cyclic peptide binder of the WBM-site of WDR5 Heteromer
P01106;
23-334
100
Crystal structure of the ternary complex of DCAF1 and WDR5 with PROTAC, OICR-40333 Heteromer
Q9Y4B6;
28-334
100A1AM2;
Modulating Protein-Protein Interactions with Visible Light Peptide Backbone Switches Heteromer
G2XKQ0;
29-334
100K;NA;
WDR5 and Histone H3 Lysine 4 dimethyl complex at 2.1 angstrom Heteromer
P68431;
29-334
99.02
WD repeat containing protein 5 (WDR5)- PER2 peptide Heteromer
O54943; P61965;
30-334
100144;CL;1PE;
WDR5 in complex with influenza NS1 C-terminal tail Heteromer
P03495;
30-334
10017×UNX;
Crystal structure of the ternary complex of DCAF1 and WDR5 with PROTAC, OICR-40407 Heteromer
Q9Y4B6;
30-334
100A1ANM;
X-ray structure of WDR5-MLL3 Win motif peptide binary complex Heteromer
Q8NEZ4;
31-334
100
Crystal structure of WDR5 in complex with the WDR5-interacting motif of MLL2 Heteromer
O14686;
31-334
100.0BTB;SO4;
X-ray structure of WDR5delta24 bound to the Kaposi's sarcoma herpesvirus LANA win motif peptide Heteromer
Q9QR71;
31-334
100.0
Crystal structure of the KANSL1-WDR5 complex. Heteromer
Q7Z3B3;
31-334
100.0GOL;
X-ray structure of WDR5-SETd1a Win motif peptide binary complex Heteromer
O15047;
31-334
100
Crystal structure of WDR5 in complex with the WDR5-interacting motif of MLL4 Heteromer
Q9UMN6;
31-334
100
Crystal structure of WDR5 in complex with a H3Q5ser peptide Heteromer
P68431;
31-334
100SRO;
Crystal structure of WDR5 in complex with H3K4me3Q5ser peptide Heteromer
P68431;
31-334
100GOL;EDO;SRO;
Crystal structure of human WDR5 in complex with monomethyl H3R2 peptide Heteromer
Q6NXT2;
31-334
100GOL;SO4;
X-ray structure of WDR5-MLL1 Win motif peptide binary complex Heteromer
Q03164;
31-334
100
WDR5 in complex with histone H3Q5his peptide Heteromer
P68431;
31-334
100
Structure of WDR5 bound to MLL1 peptide Heteromer
Q03164;
31-334
100SO4;
X-ray structure of WDR5-MLL4 Win motif peptide binary complex Heteromer
Q9UMN6;
31-334
100
Crystal structure of WDR5 in complex with the WDR5-interacting motif of SET1A Heteromer
O15047;
31-334
100
X-ray structure of WDR5-SETd1b Win motif peptide binary complex Heteromer
Q9UPS6;
31-334
100
Crystal structure of WDR5 in complex with MYC MbIIIb peptide Heteromer
P01106;
31-334
100TRS;EDO;
WDR5 in complex with unmodified H3K4 peptide Heteromer
Q6P823;
31-334
100
X-ray structure of WDR5-MLL2 Win motif peptide binary complex Heteromer
O14686;
31-334
100
WDR5 in complex with trimethylated H3K4 peptide Heteromer
Q6P823;
31-334
100
Crystal structure of the ternary complex of DCAF1 and WDR5 with PROTAC, OICR-40792 Heteromer
Q9Y4B6;
31-334
100A1ANN;
Crystal structure of the KANSL1-WDR5-KANSL2 complex. Heteromer
Q7Z3B3; Q9H9L4;
31-334
100
WDR5 in complex with monomethylated H3K4 peptide Heteromer
Q6P823;
31-334
100
Crystal structure of the ternary complex of DCAF1 and WDR5 with PROTAC, OICR-41114 Heteromer
Q9Y4B6;
31-334
100A1BAF;
Crystal structure of WDR5 in complex with the WDR5-interacting motif of SET1B Heteromer
Q9UPS6;
31-334
100.0
Crystal structure of WDR5 in complex with the WDR5-interacting motif of MLL3 Heteromer
Q8NEZ4;
31-334
100.0
WDR5 and unmodified Histone H3 complex at 2.25 Angstrom Heteromer
P68431;
31-334
98.68
Structural and biochemical insights into MLL1 core complex assembly and regulation. Heteromer
Q03164; Q15291;
31-334
100
WDR5 IN COMPLEX WITH AN RBBP5 PEPTIDE RECRUITED TO NOVEL SITE Heteromer
P61965; Q8BX09;
31-334
100GOL;
Quaternary Complex of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC Homer Heteromer
P40337; Q15369; Q15370;
30-333
1008KH;
Crystal structure of WDR5-Mb(S4) monobody complex Heteromer
31-334
100
Crystal structure of the binary complex of DCAF1 and WDR5 Heteromer
Q9Y4B6;
31-334
100IMD;
Crystal structure of Protac MS33 in complex with the WD repeat-containing protein 5 and pVHL:Elongi… Heteromer
P40337; Q15369; Q15370;
32-334
100SCN;EDO;VKA;GOL;NA;
Symmetric Dimethylation of H3 Arginine 2 is a Novel Histone Mark that Supports Euchromatin Maintena… Heteromer
P68431;
32-334
100
Crystal structure of Protac MS67 in complex with the WD repeat-containing protein 5 and pVHL:Elongi… Heteromer
P40337; Q15369; Q15370;
32-334
100GOL;X6M;
Structure of WDR5 in complex with WIN motif containing SET1B Heteromer
Q9UPS6;
32-334
100.0
WDR5 IN COMPLEX WITH AN RBBP5 PEPTIDE AND HISTONE H3 PEPTIDE Heteromer
P61965; P68433; Q8BX09;
32-334
100GOL;
Crystal structure of WDR5 in complex with the WIN peptide of PDPK1 Heteromer
O15530;
30-332
100.0
Complex between RbBP5-WDR5 and an H2B-ubiquitinated nucleosome Heteromer
P02281; P02302; P06897; P0CG47; P62799; Q15291;
32-334
100
Cryo-EM structure of MLL1 in complex with RbBP5, WDR5, SET1, and ASH2L bound to the nucleosome (Cla… Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3;
32-334
100
Cryo-EM structure of MLL1-NCP (H3K4M) complex, mode02 Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3;
32-334
100
Cryo-EM structure of MLL1 in complex with RbBP5, WDR5, SET1, and ASH2L bound to the nucleosome (Cla… Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3;
32-334
100.0
Cryo-EM structure of MLL1 in complex with RbBP5, WDR5, SET1, and ASH2L bound to the nucleosome (Cla… Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3;
32-334
100
Complex between MLL1-WRAD and an H2B-ubiquitinated nucleosome Heteromer
B4DIJ7; P02281; P06897; P0CG47; P62799; P84233; Q15291; Q9C005; Q9UBL3;
32-334
100SAH;ZN;
Cryo-EM structure of MLL1 in complex with RbBP5 and WDR5 bound to the nucleosome Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291;
32-334
100SAH;ZN;
Cryo-EM structure of MLL1 core complex bound to the nucleosome Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291; Q9C005; Q9UBL3;
32-334
100SAH;ZN;
Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with PEG linker (conformation #1) Heteromer
P40337; Q15369; Q15370;
33-334
100.015×SCN; 13×EDO;P6G;Q3X;
Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with PEG linker (conformation #2) Heteromer
P40337; Q15369; Q15370;
33-334
100SCN;Q3X;EDO;
Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with C3 linker Heteromer
P40337; Q15369; Q15370;
33-334
100.0Q3R;
Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with Aryl linker Heteromer
P40337; Q15369; Q15370;
33-333
10010×SCN;Q43;EDO;K;
Structural basis of WDR5-MLL interaction Heteromer
Q03164;
33-332
100SO4;
Cryo-EM structure of human MLL3-ubNCP complex (4.0 angstrom) Heteromer
P02281; P06897; P62799; P62979; P84233; Q15291; Q8NEZ4; Q9UBL3;
33-332
100ZN;
Cryo-EM structure of MLL1-NCP (H3K4M) complex, mode01 Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3;
33-332
100
Cryo-EM structure of human MLL1-ubNCP complex (3.2 angstrom) Heteromer
P02281; P06897; P62799; P62979; P84233; Q03164; Q15291; Q9UBL3;
33-332
100SAH;ZN;LYS;GLN;
Cryo-EM structure of human MLL1-NCP complex, binding mode1 Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3;
33-332
100SAH;ZN;LYS;GLN;
Cryo-EM structure of human MLL1-ubNCP complex (4.0 angstrom) Heteromer
P02281; P06897; P62799; P62979; P84233; Q03164; Q15291; Q9UBL3;
33-332
100SAH;ZN;
Cryo-EM structure of human MLL1-NCP complex, binding mode2 Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3;
33-332
100SAH;ZN;
Crystal structure of human WD repeat-containing protein 5 in complex with 4-(3,5-dimethoxybenzyl)-9…homo-2-mer24-334
100.0VV3;
Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC intera…homo-2-mer31-334
100QF1;
Characterization of Peptide Ligands Against WDR5 Isolated Using Phage Display Techniquehomo-2-mer31-334
100.0
WDR5 covalently modified at Y228 by (R)-2-SFhomo-2-mer31-334
100XKN;GOL;SO4;CL;
Structure of wdr5monomer11-334
100.0CL;
Crystal structure of human WDR5 in complex with (1M)-N-[(3,5-difluoro[1,1'-biphenyl]-4-yl)methyl]-6…monomer22-334
100.0YJR;
Discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the WDR5-MYC inter…monomer22-334
100QBS;SO4;
Structure of the cryo-trapped WDR5:CS-VIP8 cocrystal after illumination at 405 nm and 180 Kmonomer22-334
100
Structure of WDR5:CS-VIP8 cocrystal after illumination in situmonomer22-334
100
Structural characterisation of WDR5:CS-VIP8 interaction in cis state 1monomer22-334
100
Structure of WDR5:CS-VIP8 crystal after illumination at 405 nm and room temperaturemonomer23-334
100.0
Discovery and Structure-Based optimization of potent and selective WDR5 inhibitors containing a dih…monomer23-334
100.0Q41;
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomer24-334
100.0Q0Y;
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomer24-334
100.0Q1M;
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomer24-334
100.0Q1J;
Crystal structure of human WDR5 in complex with compound 9emonomer24-334
100.05MO;GOL;CL;EDO; 14×UNX;
WDR5delta23monomer24-334
100SO4;
Crystal structure of human WD repeat domain 5 with compound MM-401monomer24-334
100.0
Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinitymonomer28-334
100HLP;
Crystal structure of human WDR5 in complex with PTENmonomer28-334
100
Crystal structure of human WD repeat domain 5 with compound MM-402monomer28-334
100
WD repeat-containing protein 5 complexed with 4-(7-((1H-imidazol-1-yl)methyl)-5-(1-methyl-3-(triflu…monomer30-334
100BEN;UY9;
Discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the WDR5-MYC inter…monomer30-334
100QBM;
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…monomer30-334
100DMS;G2V;
Crystal structure of human WD REPEAT DOMAIN 5 in complex with 2-chloro-4-fluoro-3-methyl-N-[2-(4-me…monomer30-334
100IA9;EDO; 24×UNX;
Discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the WDR5-MYC inter…monomer30-334
100QBP;
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…monomer30-334
100G2D;
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…monomer30-334
100NA;FZM;
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complexmonomer30-334
100
WDR5 bound to 2-(3,5-dimethoxybenzyl)-7-((2-methyl-1H-imidazol-1-yl)methyl)-5-(1-methyl-3-(trifluor…monomer30-334
100BEN;M4U;
WDR5 in complex with a WIN site inhibitormonomer30-334
100HHM;SO4;DMS;
Structural basis for the specific recognition of methylated histone H3 lysine 4 by the WD-40 protei…monomer29-333
100
WDR5 in complex with Myc site fragment inhibitormonomer31-334
100.0Q8D;
WDR5 in complex with Myc site fragment inhibitormonomer31-334
100.0Q8G;
Crystal structure of human WDR5 in complex with compound 19monomer31-334
1006IQ;GOL;EDO;
Crystal structure of human WDR5 in complex with compound OICR-9429monomer31-334
10035Q;UNX;
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complexmonomer31-334
100
Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC intera…monomer31-334
100.0Q8S;
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomer31-334
100Q0M;
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomer31-334
100Q1P;Q1S;
Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinitymonomer31-334
100HLS;SO4;
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…monomer31-334
100G1Y;DMS;
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomer31-334
100Q1G;
WDR5 bound to inhibitor MM-589monomer31-334
1009BA;SO4;EDO;
WDR5delta23 bound to (2-(3-phenylpropyl)-1H-imidazol-4-yl)methanolmonomer31-334
100.0OGY;CL;
Crystal structure of human WDR5 in complex with symmetric dimethyl-L-argininemonomer31-334
100SO4;GOL;2MR;
Crystal structure of human WDR5 in complex with monomethyl L-argininemonomer31-334
100SO4;GOL;NMM;
WDR5delta23 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)acetamidemonomer31-334
100.0SO4;OH7;CL;
Crystal structure of human WDR5 in complex with MR4397monomer31-334
100ZHF;EDO;UNX;
WDR5delta23 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)benzamidemonomer31-334
100OH1;
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complexmonomer31-334
100
Crystal structure of WDR5, WD repeat domain 5 in complex with compound SGC-DS-MT-0345monomer31-334
10037F;CL;EDO;UNX;
Crystal structure of human WDR5 in complex with compound 9hmonomer31-334
1005ML;GOL;CL;EDO; 13×UNX;
Crystal structure of human WDR5 in complex with compound 9omonomer31-334
1005MN;EDO; 11×UNX;
Crystal structure of human WDR5 in complex with N-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-3-hydroxy-…monomer31-334
100YJN;
Crystal structure of human WDR5 in complex with compound 9dmonomer31-334
100.05MQ;EDO;UNX;
Crystal structure of human WD repeat domain 5 with compoundmonomer31-334
100.00BW;EDO;CL;SO4; 17×UNX;
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomer31-334
100.0Q0S;
Discovery of Potent Orally Bioavailable WD Repeat Domain 5 (WDR5) Inhibitors Using a Pharmacophore-…monomer31-334
100.0MBU;
Crystal structure of human WD repeat domain 5 with compoundmonomer31-334
100.0NP7;EDO;UNX;
Structure of WDR5 in complex with WIN motif containing MBD3C R45E/V46Gmonomer31-334
100
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complexmonomer31-334
100
WDR5 in complex with a WIN site inhibitormonomer31-334
100HH7;DMS;SO4;
Structural basis for the specific recognition of methylated histone H3 lysine 4 by the WD-40 protei…monomer30-333
100
Structure of WDR5 in complex with WIN motif containing MBD3Cmonomer31-334
100.0
WDR5 in Complex with Dimethylated H3K4 Peptidemonomer31-334
100
Crystal structure of human WDR5 in complex with L-argininemonomer31-334
100ARG;SO4;GOL;
WDR5 in complex with MLL Win motif peptidomimeticmonomer31-334
100
WDR5delta23 bound to (2-butyl-1H-imidazol-4-yl)methanolmonomer31-334
100.0OHJ;
Crystal structure of WDR5 mutant (S62A)monomer31-334
99.67
Structure of WDR5 in complex with WIN motif containing MBD3C F47Amonomer31-334
100
Crystal structure of WDR5 mutant (W330F)monomer31-334
99.67
Structure of WDR5 in complex with WIN motif containing MBD3C C44S/R45E/V46Gmonomer31-334
100
Structural characterisation of WDR5:CS-VIP8 interaction in cis state 2monomer30-333
100
Crystal structure of WDR5 mutant (W330Y)monomer31-334
99.67
Crystal structure of human WD repeat domain 5 with compound MM-102monomer31-334
100.0
Crystal structure of human WD repeat domain 5 with compound MM-101monomer31-334
100
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…monomer32-334
100.0HLM;
Crystal of WDR5 (apo-form)monomer32-334
100
WDR5delta32 bound to peptidomimeticmonomer32-334
100OK4;SO4;
WDR5delta32 bound to N-(4-(4-(hydroxymethyl)-1H-imidazol-2-yl)butyl)acrylamidemonomer32-334
100OJP;SO4;
Crystal structure of WDR5/histone H3 complexmonomer32-334
100
Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC intera…monomer32-334
100Q8M;
WDR5delta32 bound to (2-methyl-1H-imidazol-4-yl)methanolmonomer32-334
100OHG;SO4;
Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC intera…monomer32-334
100.0Q8P;
Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinitymonomer32-334
100.0HLJ;
Fine-tuning the stimulation of MLL1 methyltransferase activity by a histone H3 based peptide mimeticmonomer32-334
100.0
WDR5delta32 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)-2-phenylacetamidemonomer32-334
100OJG;SO4;
WDR5delta32 bound to ethyl 3-(4-(hydroxymethyl)-1H-imidazol-2-yl)propanoatemonomer32-334
100OJM;SO4;EDO;
WDR5delta32 bound to methyl benzyl(4-(4-(hydroxymethyl)-1H-imidazol-2-yl)butyl)carbamatemonomer32-334
100SO4;OJJ;
Crystal structure of human WDR5monomer32-334
100
WDR5delta32 bound to benzyl (4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)carbamatemonomer32-334
100OHV;SO4;
WD repeat-containing protein 5 complexed with N-[(3,5-dimethoxyphenyl)methyl]-4'-fluoro-5-{[(2E)-2-…monomer32-334
99.67Q6S;
Structure of WDR5 in complex with WIN motif containing SET1B E1750R/G1751Vmonomer32-334
100
Crystal structure of human WDR5 in complex with compound WM662monomer31-333
100X8N;GOL;SO4;PGE;
WDR5delta32 bound to methyl (4-(4-(hydroxymethyl)-1H-imidazol-2-yl)butyl)carbamatemonomer32-334
100OGM;SO4;
WDR5delta32 bound to (2-(3-methoxy-3-phenylpropyl)-1H-imidazol-4-yl)methanolmonomer32-334
100OH4;PEG;
WD repeat containing protein 5 (WDR5)- N225A mutantmonomer32-333
99.67
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…monomer31-332
100G2J;SO4;DMS;
Modulation of MLL1 Methyltransferase Activitymonomer33-332
1007DC;
Modulation of MLL1 Methyltransferase Activitymonomer33-332
1007DU;

2 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
2gnq.1.Amonomer0.9211-334
100.00
8iy5.1.Bmonomer0.6946-333
24.46